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“After years of having a dog, you know him. You know the 
meaning of his snuffs and grunts and barks. Every twitch of 
the ears is a question or statement, every wag of the tail is 
an exclamation.” 
― Robert R. Boy's Life 
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Characterization of in vitro models for the study of candidate G-quadruplex ligands targeting 
the human c-KIT proto-oncogene promoter 
 
Proto-oncogene c-KIT has been implicated in the development and growth of several tumors, 
e.g. mast cell tumors (MCT) in dogs and gastrointestinal stromal tumors (GIST) in humans.  
Several therapeutic approaches directed to the blocking of receptor tyrosine kinases (RTK), 
such as c-KIT, have been created. However, after a short period of recovery, these drugs lose 
efficiency and the tumor relapses. A new approach, aiming to control c-KIT’s transcription, is 
being tested. This approach relies on the use of small molecule inhibitors (SMI) that 
specifically block DNA secondary structures, G-quadruplexes, located on the promoter 
regions of many proto-oncogenes, including c-KIT. 
The main goal of this work is the development of in vitro models through which the study of 
candidate SMIs for human c-KIT is possible. 
An in vitro model, composed by cytotoxicity tests aimed for the determination of the SMI’s 
inhibitory concentration 50 (IC50) on two human cell lines and by real time quantitative PCR 
(qPCR) for the study of gene expression alterations, has been developed and validated. The 
cytotoxicity tests were also used to identify the IC50 of three candidate ligands for c-KIT. 
  











Caracterização de modelos in vitro para o estudo de possíveis ligandos de G-quadruplex 
dirigidos à região promotora do proto-oncogene c-KIT no Homem 
 
O proto-oncogene c-KIT tem sido relacionado com o desenvolvimento e crescimento de 
vários tumores, incluindo mastocitomas em cães e tumores do estroma gastrointestinal no 
Homem. Várias abordagens terapêuticas têm vindo a ser desenvolvidas tendo como objetivo 
bloquear os recetores de tirosina quinase, tais como c-KIT. No entanto, após um curto período 
de recuperação, estes fármacos perdem eficácia e o tumor reaparece. Está a ser testada uma 
nova abordagem, que visa controlar a transcrição de c-KIT. Esta abordagem recorre ao uso de 
pequenas moléculas inibidoras que bloqueiam, de forma específica, estruturas secundárias de 
ADN, G-quadruplex, localizadas na região promotora de vários proto-oncogenes, incluindo c-
KIT. 
O principal objetivo deste trabalho é o desenvolvimento de modelos in vitro que possam ser 
utilizados para estudar possíveis moléculas inibidoras para o c-KIT humano. 
Assim foi desenvolvido e validado um modelo in vitro, composto por testes de citotoxicidade, 
que visam determinar a concentração inibitória 50 dos ligandos, em duas linhas celulares 
humanas, e por métodos de PCR quantitativo em tempo real, para o estudo das alterações na 
expressão génica. Os testes de citotoxicidade foram também utilizados para identificar a 
concentração inibitória 50 de três possíveis ligandos para c-KIT. 
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1. Training period activities 
 
In the last year of her Integrated Masters degree, the student took a training period, of 
approximately 9 months, in the Department of Comparative Biomedicine and Food Science, 
University of Padua, Italy. The training period, which took place under the LLP/ Erasmus 
Program, was supervised by Prof. Dr. Mauro Dacasto and co-supervised by Prof. Dr. Berta 
São Braz.  
The Department where the author had her training is deeply involved in research on basic 
sciences applied to Veterinary Medicine, genetic variability in animal species, food safety and 
comparative pathology and medicine. Within this Department, the student was engaged in the 
activities peculiar of the research group in Veterinary Pharmaco- and Toxicogenomics. This 
one is composed by: 
 Mauro Dacasto (Associate Prof, DVM, PhD, Dipl. ECVPT); 
 Mery Giantin (Assistant Prof., DVM, PhD); 
 Rosa Maria Lopparelli (Technician, MSc in Agricultural Sciences, PhD); 
 Vanessa Zancanella (Post-doctoral researcher, MSc in Biotechnology for Food 
Science, PhD); 
 Eleonora Zorzan (PhD student, MSc in Biotechnology for Food Science). 
The student was involved, both, in the activities directly related to the thesis work - described 
into detail over the following chapters – and in other concurrent research projects. These ones 
were mostly related to Veterinary oncology and anti-cancer chemotherapy. Overall, the 
student had the opportunity to learn and practice basic biomolecular techniques. Among these 
ones: the extraction of nucleic acids from tissue, blood and cell samples; agarose gel 
electrophoresis; spectrophotometric determination of extracted nucleic acids quali-
quantitative traits; reverse transcription (RT); polymerase chain reaction (PCR); real time 
quantitative PCR (qPCR); cloning, and a number of techniques associated with thawing, 
maintenance, growth, splitting, and cryopreservation of established cell lines. 
As a result of her involvement, the student was inserted as a co-author in an abstract entitled 
“Characterization of the promoter region of proto-oncogene c-KIT in canine mast cell 
tumour”. This abstract was accepted as a poster and presented at the 4
th
 International Meeting 




, 2013. A copy of 
both poster and abstract of the work can be found in the “Appendix” chapter. 
Besides laboratorial activities, the student also had the opportunity to participate to classic 
Journal Club lab meetings. These ones consisted in weekly scientific discussions, during 
which a member of the research group presented a paper related with the active research 
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projects and coordinated a critic discussion with other members of the research group. The 
author not only had the opportunity to participate in the discussions, but she played an active 





































2.1. Receptor tyrosine kinases (RTK) 
 
The RTKs are the main mediators involved in the transmission of extracellular signals into the 
cell. These transmembrane receptors play an important role in processes such as cellular 
growth, proliferation, differentiation, metabolism and motility. Most RTKs bind to growth 
factors, though some bind to other polypeptide ligands (Bennasroune, Gardin, Aunis, Crémel 
& Hubert, 2004; Hubbard & Miller, 2007). It is possible to classify RTKs according to 20 
different subfamilies; each subfamily shares a homologous domain that specifies its catalytic 
tyrosine kinase function (Zwick, Bange & Ullrich, 2001). Type III RTKs are characterized by 
five extracellular immunoglobulin-like (Ig-like) domains and an intracellular kinase domain, 
which includes a hydrophilic insertion sequence of 70-100 amino acids. Members of this 
subfamily include the platelet-derived growth factor receptor alpha and beta polypeptides 
(PDGFRA and PDGFRB), serum thymidine kinase 1 (STK-1) and v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog (c-KIT) (Small et al., 1994). 
 
2.2.  The c-KIT receptor 
 
The c-KIT proto-oncogene codes for a RTK which is found to be deregulated in many 
diseases, including cancer (Lennartsson & Rönnstrand, 2012). In 1986 the v-KIT oncogene, 
the viral homolog of c-KIT, was first identified with the discovery of the Hardy-Zuckerman 4 
feline virus, a retrovirus isolated from a feline fibrosarcoma (Besmer et al., 1986). One year 
later, c-KIT was cloned and sequenced (Yarden et al., 1987). 
The c-KIT proto-oncogene is localized in the chromosome 4 of the human genome (Yarden et 
al., 1987), while on the dog genome it is mapped on chromosome 13 (Reimann-Berg, Murua 
& Nolte, 2012). In both species the gene is composed of 21 exons of which: exon 1 encodes 
the translational initiation codon and the signal peptide, exons 2-9 the remainder of the 
extracellular part of the protein, exon 10 the transmembrane region and the remaining exons, 
exons 11-21, encode the intracellular part of the receptor (Lennartsson & Rönnstrand, 2012).  
The c-KIT receptor, also known as cluster of differentiation 117 (CD117), is a type III RTK 
which binds to the stem cell factor (SCF), a cytokine responsible for the stimulation of mast 
cell growth and differentiation (Preziosi, Morini & Sarli, 2004). As illustrated in figure 1, the 
c-KIT receptor is composed by the five extracellular immunoglobulin-like domains and by 
two intracellular kinase subdomains, tyrosine kinase domain 1 and 2, separated by an 
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approximately 80 amino acids long kinase insert sequence and ends with a COOH-terminal 
tail. Between the extracellular and the intracellular portion there is a single transmembrane 
domain (Yamamoto, Tojo, Aoki & Shibuya, 1993; Lennartsson & Rönnstrand, 2012).  
 
Figure 1 - Basic structure of c-KIT (modified from Gilfillian & Rivera, 2009). 
 
The red circles represent the major tyrosine phosphorylation sites. 
 
2.3.  SCF and c-KIT regulation 
 
The SCF, also known as mast cell growth factor, steel factor or KIT ligand, is a growth factor 
expressed by fibroblasts and endothelial cells in various tissues throughout the body, 
including brain, endothelium, gametes, heart, kidney, lung, skin, liver, thymus and bone 
marrow stromal cells. The gene coding for SCF maps to chromosome 12 in humans and 15 in 
dogs. In humans, the gene is composed of 9 exons. SCF can exist as a shorter, membrane-
bound, or a longer, soluble, form. Both are able to bind c-KIT and activate its intrinsic 
tyrosine kinase activity (Lennartsson & Rönnstrand, 2012). 
The activation of c-KIT begins when a SCF homodimer simultaneously binds two c-KIT 
monomers (figure 2A). The interaction between SCF and each c-KIT monomer only involves 
the first three Ig-like domains of c-KIT, which have a complementary shape and charge, 
allowing a tight binding with SCF (figure 2B). As a result of this interaction, the two c-KIT 
monomers involved are drawn closer to each other, to the point where a conformational 
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change in each monomer takes place, enabling homotypic interactions between Ig-like 
domains 4 and 5 of the two adjacent c-KIT molecules (figure 2C). This new proximity, 
between the two receptors involved, also affects the intracellular domain, facilitating its 
activation and subsequent transphophorylation (Zhang, Zhang, Joachimiak, Schlessinger & 
Kong. 2000; Yuzawa et al., 2007). As the phosphorylation process continues in an orderly 
manner along the receptor, the phoshorylation of the juxtamembrane domain is followed by 
the phosphorylation of the kinase insert and, finally, the phosphorylation of the activation 
loop (Lennartsson & Rönnstrand, 2012). 
 
Figure 2 - Activation of c-KIT by SFC binding (modified from Lennartsson & Rönnstrand, 2012). 
 
A - The SCF protein leads the formation of c-KIT homodimers by interacting with its Ig-like domains 
1, 2 and 3; B - As a result of their interaction, SFC brings two c-KIT monomers close to each other, 
allowing interactions between Ig-like domains 4 and 5 of adjacent monomers; C - The new 
homodimeric state of c-KIT permits an efficient trans-phosphorylation along the c-KIT receptor. 
 
2.4. c-KIT’s functions 
 
Once activated, c-KIT is involved in a wide range of biologic activities, including cell 
proliferation, migration, maturation, and survival (Heissig, Werb, Rafii & Hattori, 2003; 
Metcalfe, 2008; Gregory-Bryson, Bartlett, Kiupel, Hayes & Yuzbasiyan-Gurkan, 2010). The 
c-KIT receptor is, mainly, expressed in stem and precursor cells and its expression is usually 
downregulated upon terminal differentiation, suggesting that signaling through the SCF/ c-
KIT axis might be a key element in conferring and maintenance of stemness. There are, 
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however, some types of cells that even at their final stage of differentiation continue to 
express high levels of c-KIT. Mast cells (MC), melanocytes and interstitial cells of Cajal 
might be some of the most important examples (Pittoni, Piconese, Tripodo & Colombo, 2011). 
In mast cells, adding to the previously mentioned functions, c-KIT has been associated with 
fibronectin adhesion, chemotaxis and degranulation (London, 2013). The c-KIT protein plays 
an important role during both embryogenesis and adulthood (Webster et al., 2006). 
 
2.5.  Mutations in human and canine c-KIT 
 
There are many diseases associated with an aberrant c-KIT expression, including Piebald – a 
disease that affects mammals, resulting in a pattern of non-pigmentation and white spotting –, 
atopic dermatitis, allergic rhinitis, asthma, rheumatoid arthritis (Jeong, Choi, Kim, Kim & 
Kim, 2011) and gastrointestinal motility disorders (Breuer et al., 2010). Furthermore, several 
mutations have been reported in c-KIT, in both human and canine species, all of which can 
potentially lead to the activation of c-KIT in the absence of SCF binding. Aberrant 
autophosphorylation of c-KIT, enabling the cell to develop independently from growth and 
survival signals, is one of the key features of malignance (Hanahan and Weinberg, 2000).  
According to different authors, mutations in human c-KIT occur in 50-80% of all 
gastrointestinal stromal tumors (GIST). It is estimated, however, that up to 35% of the 
remaining GIST cases exhibit mutations in PDGFRA. Since GISTs associated with c-KIT or 
PDGFRA mutations have similar downstream signaling pathways, it is thought that PDGFRA 
mutations serve as an alternative tumorigenic mechanism to c-KIT in GISTs (Gregory-Bryson 
et al., 2010; London, 2013). In GIST, the majority of c-KIT mutations occur in exons 9, 11, 13 
and 17. Exon 11 by itself comprises 90% of all c-KIT mutations. In figure 3, the main 
mutations in exon 11 are reported. Typically, these mutations consist in deletions resulting in 
perturbation of the negative regulatory function of the juxtamembrane domain, with 
consequent ligand independent c-KIT activation (Khanna & Gordon, 2009).  
Besides GIST, also acute myelogenous leukemia, pediatric mastocytosis, small cell lung 
cancer and prostate cancer have been linked to aberrant c-KIT expression. In fact, 70% of all 
small cell lung cancer cases present overexpression of c-KIT (Webster et al., 2006; Bodemer 
et al., 2010; London, 2013). In some melanoma types, specifically acral melanomas – which 
occur on the foot soles and on the palm of the hands – and mucosal melanoma, it has been 




Figure 3 - Comparison between mutation in canine and human GIST (modified from Gregory-Bryson 
et al., 2010). 
 
Codon number is based upon the human amino acid sequence [Genbank: NP_00213]. 
 
In dogs, mutations in c-KIT occur in 15-50% of mast cell tumors (MCT), and have been 
associated with tumors showing a more aggressive phenotype (Downing, Chien, Kass, Moore 
& London, 2002; Webster et al., 2006), possibly due to an increased proliferation and 
resistance to apoptosis (Gleixner et al., 2007; Letard et al., 2008). The most common type of 
mutation found in canine MCTs are internal tandem duplications (ITD) for the most part 
involving exon 11 (Webster et al., 2006). Zemke et al. (2002), as part of a study which 
analyzed 88 canine MCTs from selected canine breeds, identified c-KIT ITDs in 9% of tumors. 
However, in intermediate and high grade MCTs mutations can be present in up to 30-50 % of 
all cases (Zemke, Yamini & Yurbasiayan-Gurkan, 2002; Webster, et al., 2006). Other types of 
mutations in MCTs include deletions and point mutations in exons 8, 9, 11 and 12 of the c-
KIT proto-oncogene (Ohmori et al., 2008; Takeuchi et al., 2012). 
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2.6.  MCTs 
2.6.1. MCs and MCTs 
 
Mast cells are found in most organs and tissues of the body, it is, however, in areas that 
interface the environment, such as the skin, the lungs and the gastrointestinal tract, that MCs 
are present in higher numbers. One of the distinctive characteristics of MCs is the existence of 
granules in their cytoplasm, where inflammation mediators, including histamine, proteases, 
chemotactic factors, cytokines and metabolites of arachidonic acid are stored. These granules 
can be dyed through the use of cationic dyes that bind the granule proteoglycans, resulting in 
metachromasia, and therefore permitting the identification of mast cells (Welle, Bley, Howard 
& Rüfenacht, 2008). Mast cells play an important role in immunological, inflammatory and 
immediate-type allergic reactions. When a physical or chemical trauma occurs, or when 
stimulated by immune mechanisms, MCs respond by releasing the contents of these granules 
to the extracellular compartment (Galli, Nakae & Tsai, 2005). 
Mast cells are known to suffer neoplastic transformation, originating solitary and multiple 
tumors. The biological behavior of MCTs is highly variable, and their etiology is still 
unknown; however, likewise other tumors, MCTs are believed to have multifactorial causes 
(Gross, Ihrke, Walder & Affolter, 2005). 
In dogs, MCTs are one of the most common tumor types. When considering cutaneous tumors 
alone, MCTs account for up to 20% of all cases. Most MCTs occur in the dermis and 
subcutaneous tissue; nevertheless, visceral forms, originated in the gastrointestinal tract, 
urethra, spine bone marrow, conjunctiva, larynx, liver, oral cavity, salivary gland nasopharynx 
and spleen, can also be found (London & Seguin, 2003; Ohmori et al., 2008; Takeuchia et al., 
2010). No differences in prevalence between male and female have been identified, whereas it 
is known that some dog breeds, such as Boxers and Labrador Retrievers, are more prone to 
develop MCTs (Webster, Yuzbasiyan-Gurkan, Miller, Kaneene & Kiupel, 2007; Warland & 
Dobson, 2013). Interestingly, in Boxers and Pugs, MCTs are usually considered - from a 
histological point - of low or intermediate grade, while Shar-Peis and particularly young 
individuals are predisposed to develop poorly differentiated MCTs, which are biologically 
more aggressive (Blackwood et al., 2012). The mean age of the affected dogs is 8.5 years 






2.6.2. c-KIT and MCTs 
 
Since it was first identified, c-KIT has been considered a proto-oncogene due to the close 
connection between alterations in its expression or activity and the development of certain 
types of tumors. The involvement of c-KIT in tumorigenesis can be of two types: one in 
which the activation of c-KIT plays the main role in the initiation of the development of the 
neoplasm and another in which c-KIT has no substantial role in tumor initiation, but it 
acquires one upon tumor progression (Pittoni et al., 2011). 
As explained before, once activated c-KIT initiates a signaling cascade resulting in a wide 
array of biological activities including cell proliferation, migration, maturation and survival. 
The c-KIT receptor is expressed in both normal and neoplastic MCs presenting, however, a 
higher expression in poorly differentiated MCTs. Several c-KIT mutations have been 
identified in MCTs. Even though the complete understanding of the consequences of such 
mutations has not been achieved, it is known that c-KIT mutations and aberrant c-KIT 
localization are associated with increased expression of Ki67 and argyrophilic nuclear 
organizing regions (AgNOR), both of which are considered markers of increased cellular 
proliferation (Webster et al., 2007). 
 
2.6.3. MCTs – diagnostic and clinical presentation 
 
Upon the suspicion of a MCT, the definitive diagnosis can be achieved through cytology, 
most commonly using fine needle aspirate (FNA), and/or histopathology. Cytology of a MCT 
consists on the predominant presence of MCs. The clinical presentation of the lesions varies 
according to the tumors grade: well-differentiated cutaneous MCTs consist of slow growing, 
hairless and solitary lesions, while poorly differentiated cutaneous MCTs are characterized for 
being rapidly growing, ulcerated and pruritic lesions, sometimes surrounded by small 
“satellite lesions” (Blackwood et al., 2012).  
Clinical signs depend on both the localization and the stage of the tumor. Systemic signs, 
including anorexia, vomiting, melaena, widespread erythema, edema and gastrointestinal 
ulceration, are more frequent in visceral forms of MCTs and are associated with a poorer 







2.6.4. MCTs – treatment 
 
The therapeutic approach to each MCT case depends on different aspects, including clinical 
grading and tumor location. There are now several treatment algorithms aiming to guide 
oncologists on treatment choice (Blackwood et al., 2012). In localized, non-metastatic MCTs, 
surgical excision of the tumor is the preferable treatment choice. A 2 cm margin for grade I 
and II or a 3 cm margin for grade III, and a deep margin, including at least one fascial layer, 
should be respected (Chaffin & Thrall, 2002; Weisse,  Shofer & Sorenmo, 2002).  
Surgical excision should be considered the best local approach for MCTs, and radiation 
should be restricted to those cases where surgery did not achieve total local control 
(Blackwood et al., 2012). In intermediate grade MCTs, adjuvant radiation therapy results in a 
1-2 years disease-free interval in 81–95% of cases (Poirier et al., 2006). 
Chemotherapy, in general, is used in three different situations; (a) in cases of high-grade 
tumors where systemic therapy is required to treat, delay or prevent the dissemination of 
metastases; (b) as a preliminary treatment, prior to surgery or radiation, aiming to reduce 
tumor size and improve the likelihood of achieving complete surgery excision or tumor 
elimination through irradiation; (c) in those cases where residual microscopic disease remains 
and surgical excision and radiation are not possible (Blackwood et al., 2012).  
Several drugs and protocols are used to treat canine MCTs, reflecting the limitations with this 
approach. Prednisolone and vinblastine are most commonly used as first-line therapy and 
lomustine as part of a second-line of therapy. When choosing a chemotherapeutic agent, the 
potential drug toxic effects should always be taken in consideration. Among the 
aforementioned chemotherapeutic agents, vinblastine is known to cause perivascular 
irritation, while both vinblastine and lomustine are potentially myelosuppressive; hence, 
checking patients’ haematology, prior to each dose, is mandatory. Lomustine is also 
hepatotoxic and monitoring alanine transaminase (ALT) levels is therefore recommended 
(Blackwood et al., 2012).   
 
2.7. New therapeutic approach for cancer treatment 
 
Over the last years, many experimental settings, aiming to develop drugs capable of 
specifically blocking proteins that act as drivers of uncontrolled cancer cell growth and 
survival, have been undertaken. In general, two approaches are most commonly used: the use 




It is now possible to engineer antibodies capable of recognizing specific epitopes on a variety 
of proteins. With the development of these techniques, antibodies that recognize and bind the 
extracellular domain of RTKs or circulating growth factors, resulting on the functional 
inhibition of these proteins, have been created (London, 2013).  
A successful example of monoclonal antibody is trastuzumab (Herceptin; Genentech, South 
San Francisco, CA, USA). Trastuzumab is a monoclonal antibody targeting human epidermal 
growth factor receptor 2 (HER2), a human epidermal growth factor receptor over-expressed in 
approximately 30% of all breast cancers and other epithelial tumors (Harris, 2004). Results 
obtained are very encouraging: in women with metastatic HER2-positive breast cancer, the 
response rate is as high as 25% when used alone (Vogel et al., 2001) and when combined with 
chemotherapy, the response rate improves to 50 % (Slamon et al., 2001). As a consequence of 
these results, trastuzumab is now part of the routine therapeutic approach for women with 
HER2-positive breast cancer (Arteaga et al., 2012). 
Nevertheless, except for trastuzumab and few other cases, this strategy has not presented good 
results. Failure in therapy response might be due to the location of the receptors, since a 
considerable proportion of the expressed receptors reside inside the cell and, therefore, are not 
accessible to the antibodies in the extracellular space (Lennartsson & Rönnstrand, 2012).  
The second approach mentioned above, which also aims to inhibit specific proteins, is based 
upon the use of TKIs. These drugs can act either as competitive or allosteric inhibitors, 
blocking protein-protein interactions (Zhang, Yang & Gray, 2009). Overall, as a result of 
interrupting the survival and growth signals, these molecules prevent adenosine-5'-
triphosphate (ATP) binding to the kinase domain, inducing cell death. Comparing to 
monoclonal antibodies, TKIs are often easier to be synthesized in large and orally 
bioavailable quantities that can readily enter cells and bind the intended target (London, 2013). 
 
2.7.1. Approved TKIs for human medicine 
 
The first TKI approved for humans was imatinib (Gleevec, Novartis Oncology US, East 
Hanover NJ, USA). Imatinib is an orally administered drug, initially developed to inhibit the 
breakpoint cluster region-abelson (BCR-ABL) fusion protein and PDGFRA. Later studies 
revealed that imatinib inhibited also c-KIT (Lennartsson & Rönnstrand, 2012), presenting 
substantial action against GIST (Heinrich et al., 2003). The kinase inhibitory effect of 
imatinib is caused by its capacity to bind the ATP pocket of ABL, c-KIT and PDGFRA, 
blocking the kinase phosphorylation process and preventing, therefore, its signaling. In 
patients with chronic myelogenous leukemia (CML), in which fusion proteins are present in 
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more than 95% of the cases, treatment with imatinib results in a remission rate close to 95% 
in the chronic phase and 20-50% for patients with blast crisis. In GIST patients, response rates 
of 50-70% have been reported, far better than the 5% response rate observed with the use of 
standard chemotherapy alone (London, 2013).  
Another TKI approved for the use in humans is sunitinib (Sutent; Pfizer). Similarly to 
imatinib, sunitinib acts on several RTKs, such as vascular epithelium growth factor receptor 
(VEGFR), PDGFRA/B, c-KIT, FMS-related tyrosine kinase 1 (FLT1), colony stimulating 
factor 1 receptor (CSF1R) and RET receptor. It shares with imatinib its mechanism of action, 
as it sits in the ATP-binding pocket of the RTK. As a result of its multitargeted nature, 
sunitinib presents activity over a wide range of cancers, including GIST. In 2006, sunitinib 
was approved for the treatment of imatinib-resistant GIST and renal cell carcinoma patients. 
A surprising 61% of imatinib-resistant GIST patients, when treated with sunitinib 
demonstrated disease regression or stable disease for more than 4 months. Moreover, 65% of 
renal cell carcinoma patients, in which the treatment with interleukin-2 and/or interferon 
failed, once treated with sunitinib showed partial response or stabilization of the disease 
(London, 2009). 
 
2.7.2. Approved TKIs for veterinary medicine 
 
In veterinary medicine, two TKIs have been approved. The first one, toceranib phosphate 
(Palladia; Pfizer Animal Health, Madison, NJ, USA), is an orally available TKI blocking 
several RTKs such as VEGFR2, PDGFRA and c-KIT. Since toceranib is structurally very 
similar to sunitinib, it may have activity over other receptors too (Papaetis & Syrigos, 2009). 
In the first evaluation of toceranib in dogs, a phase I clinical trial, the TKI was tested in 
animals suffering from different types of cancer. When considering the results in patients 
suffering from MCTs, 10 of 11 dogs with c-KIT mutations responded to the therapy. In this 
first study the maximum tolerated dose was established as 3.25 mg/ kg every other day 
(q.a.d.). The main adverse effects included anorexia, diarrhea, vomiting and gastrointestinal 
bleeding. Toceranib has also been shown to induce a protein-losing nephropathy and/or 
hemolytic anemia in some patients (London, 2009). Concomitant medications proved to 
control these toxicities (London et al., 2003). A consequent trial, consisting of a placebo-
controlled randomized study with 86 dogs suffering from grade 2 and 3 MCTs, revealed a 
37.2% response rate in animals treated with toceranib, comparing to a 7.9% rate in animals 
treated with placebo. Also, of 58 animals receiving toceranib after the placebo trial, 41.4% 
experienced an objective response. Interestingly, the response rate was higher in animals with 
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c-KIT mutations (69 versus 37%: London et al., 2009).  
Toceranib was approved in 2009 and since then it has been used to treat various canine solid 
tumors, mainly after failure of primary therapy or in case of metastatic disease. High response 
rates have been registered, with clinical benefits reaching 74% in anal gland sac 
adenocarcinoma, osteaosarcoma, thyroid carcinoma and head, neck and nasal carcinomas 
(London et al., 2012). 
Several studies in which different combinations of toceranib with non-steroidal anti-
inflammatory drugs (NSAID), other chemotherapeutic drugs or radiation have been tested in 
animals suffering from MCTs revealed very encouraging results. The association of vinblastin 
and toceraninb, for instance, with a maximum dose of vinblastine at 1.6 mg/ m
2
 every other 
week and toceranib at 3.25 mg/ kg q.a.d., showed a 71% over all response rate (Robat et al., 
2012). Even the combination of toceranib with radiation showed interesting results. In a study 
in which dogs with non-reseactable MCTs received prednisolone, omeprazole, 
diphenhydramine and toceranib for a week before starting coarse fraction radiation therapy (6 
Gy once a week, for a total of 4 weeks), the response rate was 76.4% (58.8% of patients 
achieved full response and 17.6% partial response). As important as the response rate 
achieved, in this study there were no evidence of enhanced radiation-induced toxicities 
(Carlsten et al., 2012). 
The second TKI approved for veterinary use was masitinib (Kinavet; AB Science, Paris, 
France). Masitinib has shown activity over c-KIT, PDGFRA, PDGFRB and the cytoplasmic 
kinase Lyn. During a phase II study on masitinib, which included 13 animals suffering from 
grade II and III MCTs, six patients responded to treatment, two achieved complete response, 
two partial responses and in the remaining two disease stabilization was achieved. In a 
subsequent placebo-controlled phase III study, involving more than 200 dogs with non-
metastatic grade II and III MCTs, the response rate was not significantly different between the 
two groups: the response rate in the placebo group was 15%, while on the masitinib-treated 
group it was 16%. However, there was a significant difference regarding the progression time: 
the progression time in the placebo-treated group was 75 days against 118 days in the 
masitinib treated group. Masitinib has been proven to be well tolerated by both dogs and cats 
suffering from MCTs, with mild vomiting and diarrhea being the most common side effect 
(Hahn et al., 2008). Masitinib is also known to induce in some patients a mild neutropenia that 
does not predispose dogs to bacterial infection and it is often time-resolving, and the 
development of localized muscle cramping, which can be readily treated with NSAIDs 
(London, 2009). Masitinib appears to have action against both mutant and wild-type c-KIT 
(Isotani et al., 2006; Isotani et al., 2009). 
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2.8. Resistance to TKIs 
 
The immediate results obtained by treating tumor cells with TKIs have been very positive, 
unfortunately, in most cases the tumor relapses within 6 to 18 months. Resistance mechanisms 
are known only for few TKIs, i.e. imatinib, while remain only partly understood for the great 
majority of them (Rosenzweig, 2012). It has been hypothesized that several cellular 
alterations contribute to drug resistance, hindering the search for strategies that can prevent or 
circumvent this issue.  
Probably, the most studied mechanisms of drug resistance are the ones associated with 
imatinib treatment of BCR-ABL-positive CML. In these patients, drug resistance due to the 
development of point mutations in the kinase domain of BCR-ABL, preventing imatinib 
binding, has been described. Other patients develop resistance, through up-regulation of BCR-
ABL messenger ribonucleic acids (mRNA), resulting in an over-expression of the protein, 
beyond imatinib capacity to block protein function (Mahon et al., 2000). Other mechanisms 
that have been reported include elevated P-glycoprotein expression, enhanced multidrug 
efflux and activation of other growth factor pathways (London, 2013). 
Another well studied example regards patients with mutations in the endothelium growth 
factor receptor (EGFR) that respond to erlotinib, an EGFR inhibitor. Three different 
mechanisms have been described: (a) the generation of a second mutation in the EGFR ATP 
binding pocket that delays drug binding; (b) the amplification of the gene encoding met proto-
oncogene (MET) and (c) the over-expression of hepatocyte growth factor (HGF), the ligand 
for MET (Kosaka, Yamaki, Mogi & Kuwano, 2011). 
In a recent study, Gao et al. (2013) identified the development of secondary mutations in 
GIST patients after treatment with imatinib. In 65.8% of cases where drug resistance was 
developed, secondary mutations were noticed. 
As mentioned above, mechanisms of resistance to other TKIs are not so well characterized. It 
should be mentioned that drug resistance to tyrosine inhibitors can occur through epigenetic 
alterations of genes responsible for the regulation of the cellular response to kinase inhibitors 
that may follow alterations in histone acetylation/ deacetylation and chromatin and histone 
methylation (Rosenzweig, 2012).  
All the aforementioned TKIs, act as inhibitors of the kinase protein after it has been expressed. 
As a result, it has been reported that the same drug can present different response rates which 
depend from the presence of a wild-type or a mutated c-KIT genotype. For this reason recent 
researches aiming to develop drugs capable of controlling c-KIT expression have been 
undertaken. In particular, it has been hypothesized that the promote region of c-KIT could be 
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the best target of these new drugs, and two structures have been considered particularly 
attractive targets, the so-called G-quadruplex structures (Fernando et al., 2006). 
 
2.9.  G-quadruplex 
2.9.1. G-quadruplex: structure 
 
In 1953, Watson and Crick described for the first time deoxyribonucleic acids (DNA) double 
helix structure. For almost a decade, it was thought the entire genome presented this structure, 
but in 1962 Gellert and his co-workers collected fiber X-ray diffraction data on guanylic acid 
that suggested the existence of tetrameric units assembled into large helical structures in 
guanine (G) rich DNA sequences (G-quadruplexes: Bryan & Baumann, 2011). 
G-quadruplexes are DNA secondary structures formed by stacked G-tetrads. Each G-tetrad is 
composed by four Gs connected by cyclic Hoogsteen hydrogen bonding in which each of the 
four bases is the donor and the acceptor of two hydrogen bonds, thereby forming a square 
planar platform (Bryan & Baumann, 2011). The connective bond involved in the formation of 
G-tetrads is one of the many differences between G-tetrads and the normal double helix DNA. 
In the latter, nucleotides are connected by the Watson-Crick hydrogen bond, in which only 
two or three bonds exist (Yang & Okamoto, 2010).  
The ability to form stable and extensive self-connections is limited to G; no other nucleotide 
can mime a similar association. The unique G hydrogen donor and acceptor sites allow G 
nucleotides to establish such strong bonds among themselves (Bryan & Baumann, 2011). 
The guanine residues in each G-tetrad can adopt either syn or anti glycosidic conformation, 
while the residue in the antiparallel G-strand necessarily adopts the opposite conformation. G-
quadruplex structures can be formed by one or more DNA strands, to a maximum of four 
(Yang & Okamoto, 2010).  
Intramolecular G-quadruplexes, formed by one single DNA molecule, are usually composed 
by three tetrads, with four or more G-tracts involved in the tetrad formation, three or more 
loops and two flanking segments. The G-strands of intramolecular G-quadruplexes can be 
parallel, anti-parallel or hybrid and the loops, as represented in figure 4, can exhibit three 
possible conformations: strand-reversal, lateral and diagonal. Tetramolecular G-quadruplexes, 
on the other hand, tend to adopt a well-defined structure, in which all Gs display an anti-
glycosidic conformation and all DNA strands are parallel (Yang & Okamoto, 2010; Chen & 
Yang, 2012). 
Evidence suggests that the structure developed by the G-quadruplex is strictly dependent on 
its respective DNA sequence. In fact, small changes in the sequence can dramatically modify 
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the structure of the G-quadruplex or even prevent its formation. Rankin et al. (2005) have 
proved how the substitution of a single nucleotide in a four-base loop of a c-KIT G-
quadruplex sequence resulted in inhibition of the G-quadruplex formation. The formation and 





 which, as reported in figure 4, occupy the central cavity of the G-
quadruplex and neutralize the electrostatic repulsion between the O6 atoms of adjacent 




 ions are the principal cations found in vivo, thus implying 
that G-quadruplex structures are favored in physiological conditions. Between these two ions, 
K
+
 is considered to be the most relevant, due to its high intracellular concentration (K
+
 
presents a intracellular concentration ~140 mM, while Na
+
 intracellular concentration is ~10 
mM: Chen & Yang, 2012). These two cations exhibit differences in their location within the 
G-quadruplex structures: the sodium ion can present various geometries, while K
+
 is always 
equidistant between each tetrad plane, featuring a better coordination with the O6s and lower 
dehydration energy (Hud & Plavec, 2006). The ionic radius seems to be a key factor for G-
quadruplexes stability (Bryan & Baumann, 2011).  
 
Figure 4 - Schematic representation of G-quadruplex structures (modified from Chen & Yang, 2012). 
 
A – Schematic representation of a G-tetrad; B – Three schematic representations of intramolecular G-






Although the primary nucleotide sequence determines the G-quadruplex structure, some G-
rich sequences can, in the presence of different cations, give raise to different G-quadruplex 
structures. In fact, highly conserved human telomeric sequences, which only consist of 
d(TTAGGG)n are able to form various G-quadruplex structures with low energy differences 




2.9.2. Studies on G-quadruplex 
 
Various techniques have been developed to study the formation of G-quadruplexes. These, 
simple to complex, techniques allow studying the G-quadruplex formation both ex vivo and in 
vivo. One of the earliest used was a simple non-denaturating acrylamide gel electrophoresis, 
through which it can be observed how G-rich sequences present aberrant migration along the 
gel. This observation is compatible with the theory that G-rich sequences can form secondary 
structures, with consequent variations in migration.  
Even though native gel electrophoresis is still used in G-quadruplex studies, more elaborate 
techniques have been created to verify the G-tetrads structure. Circular dichroism (CD) is a 
technique in which the sample is exposed to circularly polarized light. The structure of the 
possible G-quadruplex is evaluated through the interaction between the structure and the light. 
Variations in the structure can be perceived and extrapolated according to the wavelength of 
the CD spectrum. When carried out over a certain range of temperatures, CD spectroscopy 
can also be used to determine the melting temperature (Tm), the change in enthalpy (ΔH) and 
Gibbs free energy (ΔGº) - thermodynamic parameters providing information about the 
stability of the G-quadruplex structure (Bryan & Baumann, 2011). 
A recent method, which has rapidly gained increasing importance for studying G-
quadruplexes conformation and dynamics, is the single-molecule Förster resonance energy 
transfer (FRET) spectroscopy. In this technique, the oligonucleotide is labeled with a donor 
and an acceptor fluorophore. When the oligonucleotide folds the donor fluorophore transfers 
its energy to the acceptor fluorophore. The efficiency of the donation depends on the distance 
between the two parties involved. This technique permits not only to evaluate the formation of 
DNA secondary structures, but also to analyze dynamic variations in the G-quadruplex 
structure (Bryan & Baumann, 2011).   
More detailed information on the precise molecular structures can be obtained through high-
resolution techniques, such as nuclear magnetic resonance (NMR) and X-ray crystallography. 
With NMR it is possible to determine the strands’ orientation and loops’ configuration. X-ray 
crystallography can be used to generate high-resolution structures (Bryan & Baumann, 2011). 
All the above mentioned techniques study the formation and conformation of G-quadruplex 
ex vivo. By contrast, the existence of secondary DNA structures is inherently difficult to prove 
in vivo. At present, three techniques have been created to study the existence of G-quadruplex 
in vivo. The first one is the use of specific antibodies against parallel and anti-parallel G-
quadruplexes. Through the use of this method, the existence of G-quadruplexes in ciliates 
telomeres has been demonstrated. The main concern about this approach is that the reagents 
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used for the detection of the structures may be responsible for the formation of the G-
quadruplexes, by shifting the equilibrium towards the folded form (Bryan & Baumann, 2011). 
Other techniques used in in vivo studies of G-quadruplexes include the use of either the 
radiolabeled G-quadruplex ligand 360A (2,6-N,N’-methyl-quinolinio-3-ylpyridine 
dicarboxamide) or the fluorescent G-quadruplex ligand BMVC 3,6-bis(1-methyl-4-
vinylpyridinium) carbazole diiodide (Yang & Okamoto, 2010). 
 
2.9.3. G-quadruplex in biological systems 
 
Bioinformatic analyses have identified within the human genome about 375000 sequences 
where the formation of G-quadruplex structures is possible. A better understanding of the 
functions of these structures has nowadays gained increasing interest among researchers.  
Biologically relevant G-quadruplexes were first discovered in telomeric DNA. In several 
species, it was proved the existence of guanine-guanine base-paired hairpin structures in 
single-stranded telomeric terminal sequences. As an example, in humans, telomeres contain a 
5- to 10- kb d(TTAGGG) tandem sequence with a 50- to 600 nt- single stranded 3’ overhang 
at the chromosome end, with the ability to form DNA G-quadruplexes (Chen &Yang, 2012). 
The G-quadruplex structures formed from human telomeric sequences have been the center of 
intense investigation, as, in vitro, these structures block the telomere elongation by the cancer-
associate enzyme telomerase. However, long single-strandedness is not a prerequisite for G-
quadruplex formation.  
Studies characterizing the distribution of G-rich sequences concluded that possible G-
quadruplex forming sequences are not found randomly throughout the genome. Besides their 
location in telomeric DNA, possible G-quadruplexes have been found in noncoding regions of 
the genome - especially gene promoters -, immunoglobulin switch regions, ribosomal DNA 
and certain regions of ribonucleic acid (RNA: Chen &Yang, 2012). But even their distribution 
in gene promoters is not uniform: these structures are frequently found in the promoter 
regions of proto-oncogenes, such as v-myc myelocytomatosis viral oncogene homolog (MYC), 
c-KIT and B-cell CLL/lymphoma 2 (BCL2); however, their formation in tumor suppressor 
genes is much inferior (Bryan & Baumann, 2011).  
Promoter G-quadruplexes can be classified into 4 different classes, according to the number 
of G-quadruplexes and their relative location. Class I is composed by those cases where a 
single G-quadruplex structure exists. The most studied member of this class is MYC’s G-
quadruplex (figure 5A). Class II is characterized by the presence of two distinctly different G-
quadruplexes, separated each other by about 30 base pairs (bp). The only known members of 
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this family are c-KIT’s G-quadruplexes (figure 5B). Class III is formed by those cases where 
two G-quadruplex structures are so closely positioned that they form tandem structures, which 
are more stable than individual G-quadruplexes. The G-quadruplexes present in the promoter 
region of human telomerase reverse transcriptase (TERT) are members of this class (figure 
5C). Members of class IV present multiple overlapping G-quadruplexes. Both, PDGFRB and 
BCL2 are members of this class (figure 5D: Brooks, Kendrick & Hurley, 2010). 
 
Figure 5 - Classification of unimolecular G-quadruplexes found in promoter regions (modified from 
Brooks, Kendrick & Hurley, 2010). 
 
 
Due to the high number of possible G-quadruplexes within promoter regions, these structures 
have been associated with the process of gene regulation. It was hypothesized that the 
formation of G-quadruplex structures could block gene transcription, since, when comparing 
to duplex DNA, they are more stable - presenting a higher Tm (Lipps & Rhodes, 2009). In 
MYC, for instance, a single mutation which destabilizes the formation of a G-quadruplex 
located in its promoter region, results in a threefold increase in basal transcription activity of 




Besides the aforementioned evidences on the existence of G-quadruplex in vivo, there is 
accumulating evidence that many proteins are capable of interacting with G-quadruplexes and 
in some cases can even promote their unfolding (Bryan & Baumann, 2011). 
Contrary to what happens in telomeres, where repeating tandem sequences not only exist but 
are also a key element in the G-quadruplex forming sequences, in the promoter regions the G-
quadruplex forming sequences are diverse, varying in number and length of G-tracts and 
intervening bases (Qin & Hurley, 2008). The G-quadruplexes in the promoter regions often 
contain more than four G-tracts, suggesting they can form more than one G-quadruplex 
structure through the combination of different four G-tracts, and with each G-quadruplex a 
potential combination of loop isomers due to the unequal number of Gs in each G-tract. It is 
thought that the different G-quadruplex arrangements may not be permanent, but be in a 
dynamic equilibrium with each other (Dailey, Miller, Bates, Lane & Trent, 2010). Another 
particular feature of these G-quadruplexes, lays on the fact they differ greatly in energy, due 
to the many possible arrangements of stable structures and minor unstable structures.  
A short nucleotide sequence motif, G3NG3, known to form a robust parallel-stranded structure 
motif with a 1-nt double-chain-reversal loop, has been found in all types of promoter G-
quadruplexes. In fact, due to its prevalent occurrence, it has been proposed that the G3NG3 
motif has been evolutionarily selected to serve as a stable foundation for the promoter 
intramolecular G-quadruplex structures to build upon (Yang & Okamoto, 2010). 
 
2.9.3.1. G-quadruplexes in the promoter region of human c-KIT  
 
Within the promoter of the human c-KIT proto-oncogene two G-quadruplex forming 
sequences have been identified (figure 6): c-KIT 1 and c-KIT 2. These two sequences, both 
located in a nuclease hypersensitive region, are separated by only 31 bases. The c-KIT 1 
sequence is located between 87- and 109- bp and c-KIT 2 between 140- and 160- bp relative 
to the transcription starting site (TSS: Balasubramanian, Hurley & Neidle, 2011). 
 
Figure 6 - Sequences involved in the formation of the two G-quadruplexes present in the promoter 
region of c-KIT: c-KIT 1 and c-KIT 2 (original). 
 
The G-nucleotides involved in the formation of the G-quadruplex structures are colored in red. 
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Comparatively, c-KIT 2 seems to form a standard unimolecular parallel G-quadruplex by 
using a K
+
 ion; on the other hand, the structure suggested to be formed in c-KIT 1 (figure 7), 
is not as simple. As expected, due to their proximity, similarly to c-KIT 2, c-KIT 1 also uses 
K
+
 as the stabilizing cation. NMR studies of the c-KIT 1 G-quadruplex (figure 8), revealed 
that even though its sequence includes four three-guanine runs, the backbone of one G-strand 
corner of the G-tetrad core is interrupted by a single guanine from the linker and two 
consecutive guanines from the forth three-guanine G-tract. One of the particular features of 
this G-quadruplex, lays on the existence of a snapback parallel-stranded G-quadruplex. The c-
KIT 1 is a unique structure composed by three double-chain-reversal loops; this arrangement 
is observed in normal intramolecular parallel-stranded G-quadruplex, and by an additional 
lateral loop. The c-KIT 1 G-quadruplex also includes a G3NG3 sequence, which, as explained 
above, serves as a core structure (Yang & Okamoto, 2010).  
 
Figure 8 - Schematic representation of c-KIT 1 
(modified from Qin & Hurley, 2008). 
 
 
2.9.4. G-quadruplex structures as potential anticancer drug targets 
 
With the recognition of the biological importance of G-quadruplexes, the research and 
development of compounds capable of interacting with these structures has intensified. The 
goal is to discover compounds capable of stabilizing G-quadruplex structures and therefore 
repressing gene transcription (figure 9). The concept of using G-quadruplex targeting drugs is 
a revolutionary approach in cancer treatment (Balasubramanian et al., 2011).  
Sun et al. (1997) reported for the first time the results of the interaction between G-
quadruplex ligands and telomeric G-quadruplexes. In this study, the use of G-quadruplex 
ligands resulted in the inhibition of telomerase, an enzyme which is active in most cancer 
cells and not in non-cancerous cells (Sun et al., 1997; Yang & Okamoto, 2010).  
Figure 7 - NMR structure of c-KIT 1 (taken 
from Todd, Haider, Parkinson & Neidle, 2008). 
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Since then, several families of small molecules capable of acting as inhibitors (small molecule 
inhibitors, SMIs) have been identified or created. Information about their crystal structures 
and NMR data are available providing, to some extent, information on the way by which they 
interact with each G-quadruplex structure. Different ligand families bind differently to the G-
quadruplex (Bates, Mergny & Yang, 2007).  
 
Figure 9 - Schematic representation of the transcription regulation of proto-oncogenes caused by G-
quadruplex formation mediated by SMI (modified from Ma et al., 2013). 
 
 
The conformational diversity among DNA G-quadruplexes indicates these structures can be 
targeted by specific ligands. However, a completely specific drug towards a determined G-
quadruplex structure has not yet been found nor developed. In fact, it is thought such 
specificity might not be necessary. When considering tyrosine kinases for instances, SMIs 
targeting several G-quadruplexes might result in an increased inhibitor effect. The drawback 




Several small molecule families capable of interacting with G-quadruplex structures and 
stabilizing their structures have been identified (di Antonio, et al., 2009). Efficient SMIs are 
usually composed by an extended planar system, capable of interacting with guanine-tetrads, 
and two to three positively-charged side chains, which confer an additional stability to the 
complex by binding DNA loops (Zagotto et al., 2007). In fact, ligands capable of interacting 
with G-quadruplex structures, both at the G-tetrad and loops levels, can show selectivity, not 
only for quadruplex over duplex DNA, but also for the target G-quadruplex over other G-
quadruplexes. Understanding how a SMI interacts with its G-quadruplex receptor is 
fundamental in the design and optimization of G-quadruplex ligands (Hou et al., 2012).  
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Naphthalene diimides (ND) are a SMI family which has been used in several studies as the 
quadruplex-binding core motif, due to the combination of two factors: its chemical 
accessibility and their extensive planar surfaces in its structure. These two characteristics, 
together with the presence of a cationic group within its structure, suggest NDs are 
predisposed to bind quadruplex over duplex DNA (Micco et al., 2013). Several SMI members 
of the ND family have been described so far, not only towards telomere G-quadruplexes, but 
also to promoter G-quadruplexes, namely c-KIT 1 and c-KIT 2 (Hampel et al., 2012).   
Anthraquinones derivatives (AQ) represent another important SMIs family, which has been 
studied for its DNA-interacting properties. Several AQs have been used as chemotherapeutic 
agents in anticancer treatment. Doxorubicin, for example, an anthracycline antibiotic, is being 
used as an anticancer drug against a wide range of cancer types, for over 30 years. 
Disubstituted amido-anthraquinones are considered particularly relevant SMIs, as, depending 
on their pattern of disubstituition, they can bind specifically to quadruplex over duplex DNA. 
Several studies on telomere G-quadruplexes have used AQs as ligands (Huang, 2008; Zagotto, 
2008; Huang, 2009). 
Bisantrene, a known intercalating agent, possess a structural motif characteristic of effective 
G-quadruplex ligands. Several bisantrene-analogues have been studied as possible SMIs. 
Depending on the number, location and nature of their side chains, these molecules present 
different affinity with DNA molecules (Folini et al., 2010). 
 
2.11. MCF7 and HGC27 cell-lines 
 
The use of human and animal cell-cultures in in vitro studies has become an important tool in 
biotechnology and biomedical research, since immortalized cell-lines provide a simple model 
for complex biological systems. Cell cultures are now being used in several scientific areas, 
such as toxicity testing, virology, drug screening and development, cancer research and gene 
therapy. In this project, two different cell-lines, the MCF7 and the HGC27 cell-lines, were 
used. Both cell-lines had already been used in studies aiming to develop and test SMIs 
capable of interacting with c-KITs G-quadruplexes (Bejugam et al., 2007; Gunaratnam et al., 
2009; McLuckie et al., 2011). 
The MCF7 cell-line was established from a breast adenocarcinoma human female patient, in 
1970. MCF7 cells are characterized by their epithelial-like form, for growing in monolayer, 
being capable of forming domes (see figure 10) and for presenting a doubling time of about 
38 hours (Cell Biolabs inc., 2010; ATCC, 2012). Several studies have relied on MCF7 for c-
KIT studies (Hines, Organ, Kornstein & Krystal, 1995; Treff et al., 2004). 
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Figure 10 - MCF7 cell-line (original). 
  
 
Figure 11 - HGC27 cell-line (original). 
The HGC27 is a stable cell-line, established in 1976 through the culture of the metastatic 
lymph node of an undifferentiated gastric carcinoma human patient. The HGC27 cell-line is 
characterized by its polygonal shaped cells (figure 11), for presenting a doubling time of, 
proximately, 17 hours and for adhering to glass surfaces in monolayer (Akagi & Kimoto, 
1976). The HGC27 is known for expressing both c-KIT and SCF genes (Hassan et al., 1998)
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3. Aims of the present study 
 
The c-KIT proto-oncogene is known to play an important role in the development of MCTs in 
dogs. Several approaches aiming to decrease the protein expression have been developed. 
Less than fifteen years ago, TKIs were first approved for the treatment of human cancers in 
which c-KIT was over expressed and, more recently (2009), for the treatment of canine MCTs. 
Despite the encouraging results initially obtained with these drugs, it is now known they 
present limitations, namely due to the development of resistance (Rosenzweig, 2012). 
Thus, the discovery of new molecular targets controlling c-KIT transcription represents 
nowadays a subject of interest within the scientific community. In this respect, the two G-
quadruplex structures present in the promoter region of c-KIT may represent interesting 
molecular targets for drugs aiming to modulate c-KIT expression. 
The work developed on this thesis was inserted in a collaborative research project between the 
Department of Comparative Biomedicine and Food Science and the Department of 
Pharmaceutical and Pharmacological Sciences of the University of Padua. The main goal of 
the project was the development in vitro of new SMIs capable of interacting with human and 
canine c-KIT’s G-quadruplex structures and, therefore, modulating its expression. The work 
performed for this thesis was specifically aimed to develop a valid in vitro model for the study 
of SMIs for humans. For the achievement of this goal, the work was divided into three parts: a) 
the selection of in vitro human cellular models (established cell lines) for the testing of SMIs; 
b) the execution of cytotoxicity tests, namely the measurement of the inhibitory concentration 
50 (IC50) value, by using three candidate SMIs, the aforementioned cell lines and a battery of 
cytotoxicity assays and c) the optimization and validation of qPCR assays to study the gene 
expression of c-KIT and other proto-oncogenes presenting G-quadruplex structures within 
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In medicinal chemistry, G-quadruplex (G4) represents a promising chemotherapeutic target. 
The unveiling of telomerase role in cell cycle progression and the defi nition of its mechanism 
of action prompted the search of small molecule able to block it by promoting G4 formation 
at the telomere ends. More recently, the role of conformational equilibria of G-rich sequences 
as modulator of gene expression has been assessed and opened new perspectives. In particular, 
several oncogene promoters were found to contain G-rich sequences and have been 
considered as targets for anticancer therapy. Among them, we were interested in c-kit, due to 
its widespread relevance in tumorigenesis and tumor maintenance. Interestingly, two distinct 
G-rich sequences were identified in c-kit promoter and both are now structurally characterized 
in their G4 conformation.  
The knowledge of the target is definitely a great advantage to the identification and/or 
optimization of new ligands directed towards these genomic portions. However, we also need 
solid models to assess the pharmacological efficiency of potential new drugs. In this context 
dog can represent a remarkable translational animal for human cancer.  
Indeed, mast cell tumour (MCT) is the most common (7% to 21%) cutaneous skin tumour of 
dogs and, interestingly, the MCT aggressive behaviour, (which results in poor outcome) is 
often characterized either by an overexpression or a mutational status of c-Kit. All this makes 
c-kit an important target for dog chemotherapy. Furthermore, c-kit mutations occurring in dog 
MCTs are similar to those found in human cancers, such as gastrointestinal stromal tumors 
(GIST), melanoma and mastocytosis. Therefore, canine MCT could represent a proper disease 
model to evaluate the functional consequences of c-kit abnormalities in cancer and the role of 
c-kit inhibitors in antitumor chemotherapy.  
To validate such an assumption, we started a detailed characterization of the promoter region 
of c-kit in dogs. The sequence of canine upstream promotorial sequence was cloned and 
sequenced in both healthy and MCT-suffering dogs. Then, the canine sequences were 
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compared to the human ones. In particular, large attention was devoted to clarify the 
conformational equilibria occurring in physiologically relevant conditions.  
This work represents the required preliminary step for a better understanding of MCT biology, 
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